SCHEMBL7902846

SCHEMBL7902846

CCCN1CCN(CC)C(=O)C1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
NPC1 O15118 3/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
RECQL P46063 1/20 0.40
PIK3CD O00329 1/20 0.39
ALDH1A1 P00352 1/20 0.37
THRB P10828 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PLA2G2A P14555 2/20 0.37
P2RX7 Q99572 1/20 0.36
MCHR1 Q99705 1/20 0.36
DRD2 P14416 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10687782 0.90 POLB (0.49) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL25023264 0.89 PLA2G2A (0.43) POLBNPC1RAB9APIK3CDALDH1A1
SCHEMBL9848826 0.85 P2RX7 (0.39) POLBNPC1RAB9APIK3CDL3MBTL1
SCHEMBL21698479 0.85 ALOX15 (0.43) POLBNPC1RAB9APIK3CDALDH1A1
SCHEMBL8826885 0.85 P2RX7 (0.38) NPC1RAB9AMEN1KMT2APIK3CD
SCHEMBL7896130 0.84 POLB (0.44) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL16074588 0.83 POLB (0.44) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL6888668 0.79 PIK3CD (0.60) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL9848807 0.78 PLA2G2A (0.44) POLBNPC1RAB9AMEN1KMT2A
SCHEMBL22137685 0.78 SLC6A2 (0.45) NPC1RAB9AMEN1KMT2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081311-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2024-04-18 WO disclosed
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-10-14 US disclosed
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-10-14 US disclosed
WO-2010077663-A2 SUBSTITUTED TETRACYCLIC 1H-INDENO (1,2-B) PYRIDINE-2 (5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF TNNI3, TNNT2, ALDH1A2 POLB 1458/4885NPC1 3297/4885RAB9A 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.